🔎 Trials Near Me

Почетна › Множен миелом › Калифорнија › Los Angeles

Клинички испитувања за Множен миелом во Los Angeles, CA

17 студии за Множен миелом бараат учесници на локации во и околу Los Angeles (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.

Официјален текст на студијата (англиски)

Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Се регрутираФаза 3
  • USC Norris Comprehensive Cancer Center, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07258511

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Се регрутираФаза 3
  • Valkyrie Clinical Trials, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07518186

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

Се регрутираФаза 4
  • Berenson Cancer Center, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07609940

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Се регрутираФаза 3
  • Valkyrie Clinical Trials, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05552222

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Се регрутираФаза 2
  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
Возраст 12 и постари · Сите полови · Ажурирано 22.9.2026 · NCT02693535

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Се регрутираФаза 2/3
  • Cedars-Sinai Medical Center /ID# 278238, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07095452

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Се регрутираФаза 3
  • UCLA Hematology/Oncology - Santa Monica, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 15.9.2026 · NCT06615479

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Се регрутираФаза 2
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Се регрутираФаза 1/2
  • University of Southern California /ID# 272414, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06953960

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Се регрутираФаза 3
  • Clinical Research Advisors (Korea Town Satellite Location), Los Angeles
  • Clinical Research Advisors (West Hollywood Satellite Location), Los Angeles
  • Valkyrie Clinical Trials, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 24.8.2026 · NCT06152575

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Се регрутираФаза 1/2
  • GSK Investigational Site, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT05714839

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Се регрутираФаза 1/2
  • Research Site, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT05850234

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Се регрутираФаза 1
  • Cedars-Sinai Medical Center, Los Angeles
Возраст од 18 до 85 · Сите полови · Ажурирано 10.8.2026 · NCT05887167

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Се регрутира
  • Los Angeles General Medical Center, Los Angeles
  • USC / Norris Comprehensive Cancer Center, Los Angeles
  • Cedars Sinai Medical Center, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 5.6.2026 · NCT03858205

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Се регрутираФаза 3
  • UCLA Medical Center, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 4.6.2026 · NCT05243797

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Се регрутираФаза 1/2
  • University of California Los Angeles (UCLA), Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 13.5.2026 · NCT05828511

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Се регрутираФаза 1/2
  • Valkyrie Clinical Trials, Los Angeles
Возраст 18 и постари · Сите полови · Ажурирано 3.6.2025 · NCT06119685

Испитувања за Множен миелом во други градови

Други студии во Los Angeles

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.